DOCSLIB.ORG

Potential for Photosensitivity Reactions in a and Gastrointestinal Complaints in 15%

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Potential for Photosensitivity Reactions in a and Gastrointestinal Complaints in 15% 1630 BRITISH MEDICAL JOURNAL VOLUME 284 29 MAY 1982 cluding medical care and research in their for aspirin. Discontinuations for lack of efficacy for reporting in detail the side effects en- own countries. were equivalent for benoxaprofen and aspirin but countered while treating various arthritides D HADDOCK twice as high for ibuprofen. with benoxaprofen (8 May, p 1365). We have all The experimental work reported by Dr Colin Liverpool School of Tropical Medicine, met similar problems to a greater or lesser L3 Hindson and others (p 1368) confirms the findings Liverpool 5QA of Kligmant and Griest2 in the USA and Ferguson extent. et a13 in the UK. They conclude that phototoxicity When this drug was released on the market due to benoxaprofen is a predictable side effect exactly two years ago great publicity was given and is related to exposure to both the drug and to in the general press, and claims were made Side effects of benoxaprofen ultraviolet A radiation. With appropriate measures, as if a "cure" for arthritis had been found. The exposure to UVA can be minimised. result has been that we have been overwhelmed SIR,-The BMJ of 8 May contains three The report by Drs Hugh McA Taggart and by our patients (with paper cuttings in their articles concerning side effects ofbenoxaprofen. Joan M Alderdice (p 1372) of fatalities in elderly taking benoxaprofen is remarkable for the hands) for prescription of this drug. Drs J P Halsey and N Cardoe (p 1365) report patients I hope this article will be a side effects encountered in a study of 300 striking concentration of six deaths in one practice. lesson to the No jaundice and no deaths due to hepatic failure general press when a new drug appears, not to patients treated with benoxaprofen. The side raise false hopes in the describe are qualitatively similar were reported in approximately 2200 carefully minds of the sufferers effects they followed patients who participated in clinical of this terrible disease. to those previously reported for the drug, but trials in the USA. The Inman report did not their incidence is considerably higher than mention the occurrence of jaundice. It is now M A WAJED has been noted in other studies. For example, estimated that approximately 500 000 patients Hemel Hempstead General they reported that 65-3% of patients had at have received benoxaprofen in the UK. Exclusive Hospital, least one side effect, 28-6% had photo- of the experience of Dr Taggart/Alderdice and of Hemel Hempstead, Herts HP2 4AD sensitivity, 8% onycholysis, and 18% gastro- Goudie et al' (see below), Dista UK has received intestinal side effects. The drug was with- 11 reports of jaundice. Three of these patients drawn in 34-6% of patients because of side died; other drugs and complicating underlying conditions are involved in these deaths, and further SIR,-We would like to clarify one point which effects. They noted that side effects were more investigation is being carried out to define the role in patients over 70 years of age. may be misleading in our article (8 May, frequent of benoxaprofen. p 1368). We demonstrated phototoxicity in all Recently Dr William Inman (personal com- Several clinical and pathological features of patients whom we phototested. To date, we munication) at the Drug Surveillance Unit at the Drs Taggart and Alderdice's patients are note- have investigated 14 Caucasian who University of Southampton circulated to general worthy. All of the patients were over 80 years of patients practitioners the results of a postmarketing age, and all were women. One patient had an were receiving benoxaprofen for rheumatoid surveillance study of benoxaprofen involving 5000 enlarged liver six months before benoxaprofen was conditions and who presented with no evidence patients. In those trials "events" were recorded in prescribed. All were on other medications, including of skin disease. In all 14 subjects we observed 46% of patients: 13% had cutaneous events (4% paracetamol in three. A confusing observation was immediate responses of erythema and flaring, photosensitivity); 1-5% had onycholysis; and 11% that at necropsy the major finding was intrahepatic together with subjective sensations of itching gastrointestinal events. cholestasis, a condition which is very rarely fatal. and burning. Clinical trial data accumulated in North America Decreased renal function was present in some of Although the study of Dr Halsey and Dr in over 2200 patients studied for up to three years the patients prior to therapy, and renal failure was a Cardoe (8 p showed that drug-related side effects occurred in a prominent feature of the clinical course. May, 1365) reported photo- total of 29% of patients (events of uncertain B M Goudie et a14 recently reported the sensitivity side effects in 28-6% of patients causality occurred in a further 27%' of patients): occurrence of jaundice in three patients on taking benoxaprofen, we believe there is the phototoxicity, onycholysis, or both in about 15%; benoxaprofen. All were women and over 70 years potential for photosensitivity reactions in a and gastrointestinal complaints in 15%. of age. Two recovered when benoxaprofen was much higher proportion of patients. These numbers illustrate the problems en- discontinued; one died of bronchopneumonia. countered in attempting to compare the incidence Jaundice has been reported with most of the other BRIAN DIFFEY in available non-steroidal anti-inflammatory drugs. of side effects reported various trials. The Regional Medical Physics Department, differences noted may be related to population More detailed information will be required to Dryburn Hospital, differences, but probably the most important assess the significance of the cluster of fatal cases Durham DH1 5TW factors are the method by which side effects are reported by Drs Taggart and Alderdice, but it is COLIN HINDSON sought and the manner in which they are evaluated. clear that jaundice associated with benoxaprofen Dermatology Department, Drs Halsey and Cardoe alluded to this problem is a rare event. Royal Infirmary, in interpretation when they noted that in their The increased incidence of minor side Sunderland SR2 7JE study the incidence of side effects may have been artificially high owing to coincidental non-drug effects in elderly people reported by Drs related medical conditions. They also pointed out Halsey and Cardoe, the jaundice in elderly that side effects have been reported in 150" of patients reported by Drs Taggart and Alder- dice and by Goudie et al, and the pharmaco- SIR,-At first sight, the BMJ of 8 May might patients with rheumatoid arthritis taking placebo, make any rheumatologist cringe with shame. suggesting the difficulty of assigning a causal kinetic data showing a prolonged half life of azapropazone relationship between administration of a drug and benoxaprofen in elderly patients with impaired Drug-induced lupus (p 1358), a possible side effect. of interactions (p 1373), and polyarthritis due to renal function emphasises the importance (pl373) are all mentioned. But it is To gain a true picture of the incidence of side using a reduced dose in such patients. Pre- quinidine effects with different drugs it is necessary to the three papers on benoxaprofen toxicity conduct a study taking all necessary steps to scribing information supplied by Lilly (Dista) That Dr J P attention to this which demand attention. by control bias-for example, random entry and specifically calls important Halsey and Dr N Cardoe (p 1365) is a straight- double-blind design. Such studies were done in consideration. Elderly patients should be is observed forward record of events: drug toxicity in the clinical trials of benoxaprofen sponsored by followed carefully, and if jaundice The total incidence of toxic reactions Eli Lilly and Company. In those trials photo- benoxaprofen should be promptly dis- practice. sensitivity and onycholysis were identified as side continued. was very high, but we need to see the same effects of benoxaprofen but not of aspirin or reporting system used for other drugs-that is, ibuprofen. The incidence of gastrointestinal side W IAN H SHEDDEN a control group. What was the incidence of Vice President, Lilly Research effects was similar to that of ibuprofen but about Laboratories toxicity due to other drugs taken singly or in half that observed with aspirin. Unlike the Eli Lilly and Company, combinations under the same conditions ? gastrointestinal side effects, photosensitivity is Indianapolis, Indiana The phototoxic reaction described and dis- generally preventable and can be minimised by cussed in Dr Colin Hindson and colleagues' of to the use of Kligman AM, Kaidbey KH. Eturopean Joutrnal of avoidance exposure sun, protective Rheumnatology and Inflammrnation. 1982 ,5 :127-37. paper (p 1368) can be most uncomfortable clothing, and the use of sunscreen lotions. 2Griest MC, Oxols II, Ridolfo AS, Muus JC. Eu4ropean Drs Halsey and Cardoe comment on the 7ournal of Rheumatology and Inflammation 1982; for patients. We have known about this now with which were withdrawn 5:138-47. for over two years, and the company concerned frequency patients Ferguson J, Addo HA, McG PE, Woodcock KR, from benoxaprofen because of the occurence of Johnson BE, Frain-Bell W. Br J Derm (in press). have issued cards for patients warning them side effects. This gives an incomplete picture. A 4 Goudie BM, Birnie GF, Watkinson G, MacSween how to reduce its frequency. Were any of a is the RNM, Kissen LH, Cunningham NE. Lancet better measure of drug's acceptability 1982 ;i :959. Dr Hindson and colleagues' patients so frequency of drug discontinuance due both to side warned ? effects and to lack of efficacy. In the six-month For the past three or four years it has been controlled trials drug was withdrawn for both reasons in 17`o of benoxaprofen patients, 230' of my practice to ask of pharmaceutical represen- those on ibuprofen, and 25°" of those on aspirin.
Load more

Recommended publications
  • United States Patent (19) 11 Patent Number: 5,955,504 Wechter Et Al
    USOO5955504A United States Patent (19) 11 Patent Number: 5,955,504 Wechter et al. (45) Date of Patent: Sep. 21, 1999 54 COLORECTAL CHEMOPROTECTIVE Marnett, “Aspirin and the Potential Role of Prostaglandins COMPOSITION AND METHOD OF in Colon Cancer, Cancer Research, 1992; 52:5575–89. PREVENTING COLORECTAL CANCER Welberg et al., “Proliferation Rate of Colonic Mucosa in Normal Subjects and Patients with Colonic Neoplasms: A 75 Inventors: William J. Wechter; John D. Refined Immunohistochemical Method.” J. Clin Pathol, McCracken, both of Redlands, Calif. 1990; 43:453-456. Thun et al., “Aspirin Use and Reduced Risk of Fatal Colon 73 Assignee: Loma Linda University Medical Cancer." N Engl J Med 1991; 325:1593-6. Center, Loma Linda, Calif. Peleg, et al., “Aspirin and Nonsteroidal Anti-inflammatory Drug Use and the Risk of Subsequent Colorectal Cancer.” 21 Appl. No.: 08/402,797 Arch Intern Med. 1994, 154:394–399. 22 Filed: Mar 13, 1995 Gridley, et al., “Incidence of Cancer among Patients With Rheumatoid Arthritis J. Natl Cancer Inst 1993 85:307-311. 51) Int. Cl. .......................... A61K 31/19; A61K 31/40; Labayle, et al., “Sulindac Causes Regression Of Rectal A61K 31/42 Polyps. In Familial Adenomatous Polyposis” Gastroenterol 52 U.S. Cl. .......................... 514/568; 514/569; 514/428; ogy 1991 101:635-639. 514/416; 514/375 Rigau, et al., “Effects Of Long-Term Sulindac Therapy On 58 Field of Search ..................................... 514/568, 570, Colonic Polyposis” Annals of Internal Medicine 1991 514/569, 428, 416, 375 11.5:952-954. Giardiello.et al., “Treatment Of Colonic and Rectal 56) References Cited Adenomas With Sulindac In Familial Adenomatous Poly U.S.
    [Show full text]
  • Fatal Hepatitis Associated with Diclofenac
    Gut: first published as 10.1136/gut.27.11.1390 on 1 November 1986. Downloaded from Gut, 1986, 27, 1390-1393 Case reports Fatal hepatitis associated with diclofenac E G BREEN, J McNICHOLL, E COSGROVE, J MCCABE, AND F M STEVENS From the Department of Medicine, Regional Hospital, Galway, Eire SUMMARY Non-steroidal anti-inflammatory agents (NSAIDS) are a well recognised cause of hepatotoxicity. Diclofenac, a relatively new NSAID, was first introduced into the UK in 1979. Five cases of hepatitis have recently been reported, principally in the French literature. -5 We report the first fulminant case of hepatitis in the English literature in a patient taking diclofenac and indomethacin. Diclofenac is a member of the arylalkanoic group of 100 mg per day for five weeks. Ferrous sulphate one NSAIDS (Fig. 1). Three other agents in this group tablet daily was added on 16 May. The patient was have been shown to be significantly hepatotoxic. admitted to hospital on 26 June. A week before this Ibufenac was withdrawn from circulation because of he had felt unwell with anorexia, nausea, abdominal the frequent rise in transaminases,6 7 the use of discomfort, and dark urine. On admission he was benoxaprofen was stopped in Britain after 10 icteric, the liver edge was palpable 4 cm below the patients died with hepatitis8 9 and more recently a costal margin and there were no signs of chronic fatal case of hepatitis due to pirprofen has been liver disease. Ultrasound showed early ascites with reported."' Early reports about diclofenac showed no obstruction of the biliary tract.
    [Show full text]
  • Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation, Final, July 2009
    Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) July 2009 Drug Safety Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 51, rm. 2201 Silver Spring, MD 20993-0002 Tel: 301-796-3400; Fax: 301-847-8714; E-mail: [email protected] http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or Office of Communication, Outreach, and Development, HFM-40 Center for Biologics Evaluation and Research Food and Drug Administration 1401 Rockville Pike, Rockville, MD 20852-1448 Tel: 800-835-4709 or 301-827-1800 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) July 2009 Drug Safety TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. BACKGROUND: DILI ................................................................................................... 2 III. SIGNALS OF DILI AND HY’S
    [Show full text]
  • Benoxaprofen Irony Is Inescapable That While Manuscripts
    BRITISH MEDICAL JOURNAL VOLUME 285 18 SEPTEMBER 1982 809 Br Med J (Clin Res Ed): first published as 10.1136/bmj.285.6344.809-a on 18 September 1982. Downloaded from favourable groups of alcoholics (such as single, trials and post-marketing surveillance pro- the carefully controlled and monitored clinical divorced, or widowed men and women) is as grammes, often undergo extensive revision trial. Unless there is prompt reporting of the yet unknown but may appear doubtful to the before acceptance for publication, paid results of such trials by the sponsoring drug practising clinician.3 The statement that, advertisements extolling only the virtues of company to all governmental agencies in "Treatment may actually make some alco- various products generally are accepted countries marketing or planning to market a holics worse" by protecting them from the without modification. particular drug, the Committee on Safety of consequences of their drinking or by fostering In the face of the need to maintain fiscal Medicines, the Food and Drug Administration, inactivity surely applies only to utterly inade- viability while upholding the highest editorial and similar agencies in other countries will quate "treatment." The risks arising from the standards, what is a medical journal to do in not be acting on the best available information. behaviour of well-meaning "enablers" who regard to advertising? The issue needs to be shelter the alcoholic from experiencing the explored by both editors and medical associa- SIDNEY M WOLFE painful effects of his drinking on himself (and tions at their meetings. One proposal has been EVE BARGMANN others) and the importance of fostering the raised' and seconded2 for a "physician Health Research Group, patient's responsibility for his recovery, his boycott" of drugs that are unethically pro- Washington DC 20036 own initiative, and active participation in the moted.
    [Show full text]
  • Benoxaprofen
    BRITISH LONDON, SATURDAY 14 AUGUST 1982 Br Med J (Clin Res Ed): first published as 10.1136/bmj.285.6340.459 on 14 August 1982. Downloaded from MEDICAL^s JOURNAL Benoxaprofen Two years after benoxaprofen (Opren) was launched in a The mode of action of benoxaprofen appears to differ blaze of publicity the Committee on Safety of Medicines has from that of other non-steroidal anti-inflammatory agents. It suspended its product licence on the grounds of concern acts directly on mononuclear cells, inhibiting their chemotactic about serious side effects (see p 519). The public has been response; it inhibits the lipoxygenase enzyme; and it has a alarmed by the total of 61 deaths in patients, mostly elderly, mild inhibitory action on the formation of other prosta- taking benoxaprofen and by the admission of the Committee glandins.'8 19 This combination of properties is of great on Safety of Medicines that it has received 3500 reports of theoretical interest, since nearly all other non-steroidal adverse reactions. Has the Committee on Safety of Medicines anti-inflammatory drugs appear to act by inhibiting prosta- acted too slowly on this occasion ? What are the- lessons to be glandin synthetase. There is some preliminary evidence that learnt ? benoxaprofen may have disease-modifying properties in Firstly, the benoxaprofen affair shows the dangers of current rheumatoid arthritis.20 marketing policies by some pharmaceutical companies. After A drug with unusual properties may be expected to have its clinical trials the drug was put on to the market with massive unusual side effects-and both the frequency and nature of publicity on radio and in newspapers encouraging patients to these effects have been surprising.
    [Show full text]
  • An in Vitro Approach to Detect Metabolite Toxicity Due to CYP3A4
    Toxicology 216 (2005) 154–167 An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics Luisella Vignati ∗, Elisa Turlizzi 1, Sonia Monaci, Pietro Grossi, Ruben de Kanter, Mario Monshouwer 2 Department of Pre-Clinical Development, Nerviano Medical Sciences S.r.l., V.le Pasteur, 10, 20014, Nerviano, MI, Italy Received 22 June 2005; received in revised form 3 August 2005; accepted 3 August 2005 Available online 19 September 2005 Abstract Many adverse drug reactions are caused by the cytochrome P450 (CYP) dependent activation of drugs into reactive metabolites. In order to reduce attrition due to metabolism-mediated toxicity and to improve safety of drug candidates, we developed two in vitro cell-based assays by combining an activating system (human CYP3A4) with target cells (HepG2 cells): in the first method we incubated microsomes containing cDNA-expressed CYP3A4 together with HepG2 cells; in the second approach HepG2 cells were transiently transfected with CYP3A4. In both assay systems, CYP3A4 catalyzed metabolism was found to be comparable to the high levels reported in hepatocytes. Both assay systems were used to study ten CYP3A4 substrates known for their potential to form metabolites that exhibit higher toxicity than the parent compounds. Several endpoints of toxicity were evaluated, and the measurement of MTT reduction and intracellular ATP levels were selected to assess cell viability. Results demonstrated that both assay systems are capable to metabolize the test compounds leading to increased toxicity, compared to their respective control systems. The co-incubation with the CYP3A4 inhibitor ketoconazole confirmed that the formation of reactive metabolites was CYP3A4 dependent.
    [Show full text]
  • Reviewer Guidance
    Reviewer Guidance Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2005 Good Review Practices Reviewer Guidance Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review Additional copies are available from: Office of Training and Communication Division of Drug Information, HFD-240 Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/cder/guidance/index.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2005 Good Review Practices TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. GENERAL GUIDANCE ON THE CLINICAL SAFETY REVIEW .......................... 2 A. Introduction....................................................................................................................................2 B. Explanation of Terms ....................................................................................................................3 C. Overview of the Safety Review .....................................................................................................4 D. Differences in Approach to Safety and Effectiveness Data ........................................................4
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs B.L
    Br. J. clin. Pharmac. (1983), 16, 633-638 A METHOD FOR PREDICTING THE PHOTOTOXICITY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS B.L. DIFFEY1 & S. BROWN2 Departments of Medical Physics' and Pharmacy2, Dryburn Hospital, Durham, DH1 5TW 1 The photosensitisation potential of several non-steroidal anti-inflammatory drugs (NSAIDs) has been investigated in vivo using an irradiation monochromator. 2 Evidence ofabnormal, immediate photosensitivity was obtained in 13 of the 38 patients taking one of four out of seven different NSAIDs. 3 A simple mathematical model was developed to predict the likelihood of photosensitivity occurring with a given drug by considering the mass of drug normally ingested, the spectral absorption characteristics of the drug, and the quantity and spectral quality of the radiation (e.g. sunlight) to which the patient may be exposed. Keywords phototoxicity non-steroidal anti-inflammatory drugs Introduction The non-steroidal anti-inflammatory drugs (NSAIDs) differences in skin pigmentation reflecting variations have gained prominence in recent years as useful in the penetration of light into the skin. therapeutic agents in the management of rheumatoid The NSAIDs, although chemically distinct, share and osteoarthritis. However several of these drugs many common properties. The exact mode of action have been reported as inducing adverse cutaneous of each drug is not fully understood, but all these photosensitive reactions (Committee on Safety of drugs are potent inhibitors of the enzyme prosta- Medicines, personal communication). The photo- glandin synthetase (Simon & Mills, 1980). This sensitisation potential of many of these drugs, parti- property undoubtedly plays an important part in the cularly benoxaprofen, has subsequently been con- anti-inflammatory effect, but there is no clearly de- firmed by laboratory investigation (Wiskemann, 1981; fined relationship between the inhibitory potency of a Kligman & Kaidbey, 1982; Ferguson et al., 1982; drug against prostaglandin synthetase in vitro and Diffey & Daymond, 1983; Diffey etal., 1983).
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Agents and the Gastrointestinal Tract
    Postgrad Med J: first published as 10.1136/pgmj.62.723.23 on 1 January 1986. Downloaded from Postgraduate Medical Journal (1986) 62, 23-28 At our mother's knee - an occasional review Non-steroidal anti-inflammatory agents and the gastrointestinal tract K.W. Somerville and C.J. Hawkey Department ofTherapeutics, University Hospital, Nottingham NG7 2UH, UK. Non-steroidal anti-inflammatory drugs (NSAIDs) pattern with gastritis, mucosal erosions and/or occult have had a bad press recently. The proliferation of bleeding (Roth et al., 1963; Hurley & Crandall, 1964). these widely used agents has attracted the derogatory Similar changes are seen in some animals given high appellation 'me too'. Some, such as benoxaprofen, doses of other NSAIDs but there is wide interspecies zomepirac, indoprofen and a controlled delivery in- variation: unlike rats, domestic pigs have minimal domethacin formulation ('Osmosin'), have been with- duodenal mucosal changes after 15 mg/kg indometh- drawn because of concern about adverse drug effects acin (Rainsford & Willis, 1982). including gastrointestinal bleeding (benoxaprofen) Acute gastro-duodenal changes are described in (Editorial, 1982) and bowel perforation ('Osmosin') man with many NSAIDs and aspirin in particular. For (Day, 1983). Concern has been expressed for as long as example Caruso & Bianchi Porro (1980) compared 10 NSAIDs have been available and there is little doubt NSAIDs plus corticosteroids given to 249 patients that acute administration of many of them causes with arthritis; 78 (31 %) developed lesions in the upper gastric erosions in animals and provokes microscopic gastrointestinal tract identified at gastroscopy during by copyright. bleeding in man. What remains controversial is a 12 month follow-up, more with multiple (51 %) than whether there is a causative link between NSAID single (23%) drug treatment.
    [Show full text]
  • Inflammatory Drug
    Abbreviations used: AR(s), adverse hepatotoxicity, 17 reaction(s); ADR(s), adverse drug manufacturers, 9 reaction(s); NSAID(s), non-steroid anti­ amorfazone, trade mark names and inflammatory drug(s) manufacturers, 9 Amuno, generic name and manufacturer, 12 anaemia absorption interactions, drug, 180-1 aplastic, 83 acemetacin, trade mark names and report rate, 33 manufacturers, 8 haemolytic, 84-5 acetyl salicylic acid, see Aspirin in rheumatoid patients, inappropriate action, drug, ~ pharmacoactivity therapy, 250 activation (of drugs), 243-5, 246, 247 anaphylaxis/anaphylactoid reactions, 17, pathway, 244 81 Actol, generic name and manufacturer, 13 Anaprox, generic name and manufacturer, Actosal, generic name and manufacturer, 13 9 angioedema, 6 acyl-coenzyme A formation, 221-2 angiotensin-converting enzyme, 195, 196 adjuvant induced arthritis, ~ inhibitors arthritis function, 195 Af1oxan, generic name and manufacturer, NSAID interactions with, 195-200 14 animal(s) age see also elderly experimentation, ethics of, 267 gastrointestinal susceptibility re­ inter species differences in lated to, 164, 286-8 propionate chiral inversion, use of anti-arthritics correlated 222-3, 223 with, 152 Ansaid, generic name and manufacturer, aged, the, ~ elderly 11 agranulocytosis antacids, 292 incidence, 7, 100-2 passim effect on drug absorption, 180, 181 in Sweden, 66, 67 NSAID interactions with, 185, 193 pyrazolone-induced, 7, 99-104 anthranilic acid, relative safety, 18 analytical epidemiological anti-arthritic drugs, ~ antirheumatic studies, 101-3 drugs
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]
  • Supervision Registers for Mentally Ill People Medicolegal Issues Seem Likely to Dominate Decisions by Clinicians
    LONDON, SATURDAY 3 SEPTEMBER 1994 Supervision registers for mentally ill people Medicolegal issues seem likely to dominate decisions by clinicians The Department of Health and the Royal College of personal liability, but they are time consuming and Psychiatrists do not see eye to eye over the introduction of expensive. Judicial review in relation to child abuse supervision registers for patients in the community who are registers is increasing, and supervision registers seem likely judged to be at risk. In a recent exchange of corres- to follow their example. pondence the college expressed "strong concerns" about The introduction of supervision registers will be an invi- guidelines issued by the department for the introduction of tation to litigation. Nowhere is this clearer than in the case the register on 1 October. 1-3 Further discussions are of a failure to include a person on the register, when in the planned, but the differences will not easily be resolved. event of a subsequent untoward incident this decision may The issue is much more than a little local difficulty in retrospect create an impression of negligence, whatever between psychiatrists and the Department of Health; its the reality. The prediction of dangerousness is far from an resolution will be important for all mental health profes- exact science, and a court might recognise that-but only sionals and for purchasers of psychiatric services. The at trial, after the defendants have undergone considerable college is concerned that the criteria for including patients frustration, professional soul searching, and expense. on supervision registers are too broad and about the sub- Violent incidents and tragic suicides provoke enormous stantial costs of setting up and servicing the registers.
    [Show full text]